SCHEMBL21769296

SCHEMBL21769296

CCOC(=O)C(=N)C(=O)Cc1ccc(F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
KDM4E B2RXH2 4/20 0.50
TDP1 Q9NUW8 3/20 0.50
GAA P10253 2/20 0.50
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
LMNA P02545 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
POLB P06746 2/20 0.46
APEX1 P27695 1/20 0.46
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.45
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
CES2 O00748 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21185428 0.87 MEN1 (0.48) MAPTTDP1GAAKMT2AMEN1
SCHEMBL5809024 0.87 MAPT (0.54) MAPTKDM4ETDP1GAAKMT2A
SCHEMBL13351790 0.84 EGFR (0.46) KDM4ETDP1GAAKMT2AMEN1
SCHEMBL7971820 0.84 CES2 (0.52) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL2596988 0.84 MAPT (0.51) MAPTKDM4ETDP1GAAKMT2A
SCHEMBL15955979 0.78 MAPT (0.53) MAPTKDM4ETDP1GAAKMT2A
SCHEMBL21185442 0.78 MAPT (0.49) MAPTKDM4ETDP1GAAKMT2A
SCHEMBL21176846 0.78 KMT2A (0.46) MAPTKDM4ETDP1GAAKMT2A
SCHEMBL22684774 0.78 MAPT (0.49) MAPTKDM4ETDP1GAAKMT2A
SCHEMBL22684775 0.78 MAPT (0.49) MAPTKDM4ETDP1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220073496-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR TRANSTHERA SCIENCES (NANJING), INC. (CN) 2022-03-10 US disclosed
EP-3842425-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR Nanjing Transthera Biosciences Co., Ltd. (CN) 2021-06-30 EP disclosed
WO-2020038460-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR 南京药捷安康生物科技有限公司 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073496-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR CSF1R, CSF3R, FLT3 MAPT 2342/4885KDM4E 2855/4885TDP1 1719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.